RZV recombinant zoster
Selected indexed studies
- Effectiveness of Recombinant Zoster Vaccine Against Herpes Zoster in a Real-World Setting. (Ann Intern Med, 2024) [PMID:38190712]
- Cost-effectiveness of the recombinant zoster vaccine (RZV) against herpes zoster: An updated critical review. (Hum Vaccin Immunother, 2023) [PMID:36916240]
- Effectiveness and safety of recombinant zoster vaccine: A review of real-world evidence. (Hum Vaccin Immunother, 2023) [PMID:37967254]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Herpes Zoster Vaccines. (2021) pubmed
- A practitioner's guide to the recombinant zoster vaccine: review of national vaccination recommendations. (2021) pubmed
- Effectiveness of Recombinant Zoster Vaccine Against Herpes Zoster in a Real-World Setting. (2024) pubmed
- Cost-effectiveness of the recombinant zoster vaccine (RZV) against herpes zoster: An updated critical review. (2023) pubmed
- Effectiveness and safety of recombinant zoster vaccine: A review of real-world evidence. (2023) pubmed
- Herpes Zoster and Post-Herpetic Neuralgia-Diagnosis, Treatment, and Vaccination Strategies. (2024) pubmed
- Risk of Herpes Zoster Ophthalmicus Recurrence After Recombinant Zoster Vaccination. (2024) pubmed
- Systematic review and meta-analysis of recombinant herpes zoster vaccine in immunocompromised populations. (2024) pubmed
- Recombinant Zoster Vaccine Reduces 3-Year Cardiovascular Risk: Insights From a Multi-Centered Database. (2023) pubmed
- Risk of Guillain-Barré Syndrome Following Recombinant Zoster Vaccine in Medicare Beneficiaries. (2021) pubmed